|
1
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bollag G, Hirth P, Tsai J, Zhang J,
Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al:
Clinical efficacy of a RAF inhibitor needs broad target blockade in
BRAF-mutant melanoma. Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: BRIM-3 Study Group: Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
King AJ, Arnone MR, Bleam MR, Moss KG,
Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A,
Kane-Carson LS, et al: Dabrafenib; preclinical characterization,
increased efficacy when combined with trametinib, while BRAF/MEK
tool combination reduced skin lesions. PLoS One. 8:e675832013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoeflich KP, Merchant M, Orr C, Chan J,
Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, et al:
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K
inhibitor GDC-0941 triggers robust apoptosis and tumor growth
inhibition. Cancer Res. 72:210–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larkin J, Ascierto PA, Dréno B, Atkinson
V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas
L, et al: Combined vemurafenib and cobimetinib in BRAF-mutated
melanoma. N Engl J Med. 371:1867–1876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, De Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Combined BRAF and MEK inhibition versus BRAF
inhibition alone in melanoma. N Engl J Med. 371:1877–1888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Villanueva J, Vultur A, Lee JT,
Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu
X, Gimotty PA, Kee D, et al: Acquired resistance to BRAF inhibitors
mediated by a RAF kinase switch in melanoma can be overcome by
cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18:683–695. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi H, Moriceau G, Kong X, Lee MK, Lee H,
Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, et al: Melanoma
whole-exome sequencing identifies V600EB-RAF amplification-mediated
acquired B-RAF inhibitor resistance. Nat Commun. 3:7242012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johannessen CM, Boehm JS, Kim SY, Thomas
SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP,
Barretina J, et al: COT drives resistance to RAF inhibition through
MAP kinase pathway reactivation. Nature. 468:968–972. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Poulikakos PI, Persaud Y, Janakiraman M,
Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al:
RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E). Nature. 480:387–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Long GV, Wilmott JS, Haydu LE, Tembe V,
Sharma R, Rizos H, Thompson JF, Howle J, Scolyer RA and Kefford RF:
Effects of BRAF inhibitors on human melanoma tissue before
treatment, early during treatment, and on progression. Pigment Cell
Melanoma Res. 26:499–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bivona TG and Doebele RC: A framework for
understanding and targeting residual disease in oncogene-driven
solid cancers. Nat Med. 22:472–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sharma SV, Lee DY, Li B, Quinlan MP,
Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach
MA, et al: A chromatin-mediated reversible drug-tolerant state in
cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
KEYNOTE-006 investigators: Pembrolizumab versus Ipilimumab in
advanced melanoma. N Engl J Med. 372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boni A, Cogdill AP, Dang P, Udayakumar D,
Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher
DE, et al: Selective BRAFV600E inhibition enhances T-cell
recognition of melanoma without affecting lymphocyte function.
Cancer Res. 70:5213–5219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Frederick DT, Piris A, Cogdill AP, Cooper
ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et
al: BRAF inhibition is associated with enhanced melanoma antigen
expression and a more favorable tumor microenvironment in patients
with metastatic melanoma. Clin Cancer Res. 19:1225–1231. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilmott JS, Long GV, Howle JR, Haydu LE,
Sharma RN, Thompson JF, Kefford RF, Hersey P and Scolyer RA:
Selective BRAF inhibitors induce marked T-cell infiltration into
human metastatic melanoma. Clin Cancer Res. 18:1386–1394. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
von Euw EM, Barrio MM, Furman D, Bianchini
M, Levy EM, Yee C, Li Y, Wainstok R and Mordoh J: Monocyte-derived
dendritic cells loaded with a mixture of apoptotic/necrotic
melanoma cells efficiently cross-present gp100 and MART-1 antigens
to specific CD8+ T lymphocytes. J Transl Med. 5:192007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barrio MM, De Motta PT, Kaplan J, von Euw
EM, Bravo AI, Chacón RD and Mordoh J: A phase I study of an
allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma
patients. J Immunother. 29:444–454. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barrio MM, Abes R, Colombo M, Pizzurro G,
Boix C, Roberti MP, Gélizé E, Rodriguez-Zubieta M, Mordoh J and
Teillaud JL: Human macrophages and dendritic cells can equally
present MART-1 antigen to CD8+ T cells after phagocytosis of
gamma-irradiated melanoma cells. PLoS One. 7:e403112012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Debacq-Chainiaux F, Erusalimsky JD,
Campisi J and Toussaint O: Protocols to detect
senescence-associated beta-galactosidase (SA-βgal) activity, a
biomarker of senescent cells in culture and in vivo. Nat Protoc.
4:1798–1806. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yee C, Thompson JA, Byrd D, Riddell SR,
Roche P, Celis E and Greenberg PD: Adoptive T cell therapy using
antigen-specific CD8+ T cell clones for the treatment of patients
with metastatic melanoma: In vivo persistence, migration, and
antitumor effect of transferred T cells. Proc Natl Acad Sci USA.
99:16168–16173. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boiko AD, Razorenova OV, van De Rijn M,
Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan
MJ, et al: Human melanoma-initiating cells express neural crest
nerve growth factor receptor CD271. Nature. 466:133–137. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schatton T, Murphy GF, Frank NY, Yamaura
K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM,
Weishaupt C, et al: Identification of cells initiating human
melanomas. Nature. 451:345–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Frank NY, Margaryan A, Huang Y, Schatton
T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W and Frank MH:
ABCB5-mediated doxorubicin transport and chemoresistance in human
malignant melanoma. Cancer Res. 65:4320–4333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Haferkamp S, Borst A, Adam C, Becker TM,
Motschenbacher S, Windhövel S, Hufnagel AL, Houben R and
Meierjohann S: Vemurafenib induces senescence features in melanoma
cells. J Invest Dermatol. 133:1601–1609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao
Y, Piao Y, Liu J, Cheng W, Bi X, et al: Encorafenib (LGX818), a
potent BRAF inhibitor, induces senescence accompanied by autophagy
in BRAFV600E melanoma cells. Cancer Lett. 370:332–344. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Michaloglou C, Vredeveld LC, Soengas MS,
Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi
WJ and Peeper DS: BRAFE600-associated senescence-like cell cycle
arrest of human naevi. Nature. 436:720–724. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aris M, Zubieta MR, Colombo M, Arriaga JM,
Bianchini M, Alperovich M, Bravo AI, Barrio MM and Mordoh J:
MART-1- and gp100-expressing and -non-expressing melanoma cells are
equally proliferative in tumors and clonogenic in vitro. J Invest
Dermatol. 132:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Holderfield M, Deuker MM, McCormick F and
McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated
melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Redmer T, Welte Y, Behrens D, Fichtner I,
Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R and
Regenbrecht CR: The nerve growth factor receptor CD271 is crucial
to maintain tumorigenicity and stem-like properties of melanoma
cells. PLoS One. 9:e925962014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cheli Y, Bonnazi VF, Jacquel A, Allegra M,
De Donatis GM, Bahadoran P, Bertolotto C and Ballotti R: CD271 is
an imperfect marker for melanoma initiating cells. Oncotarget.
5:5272–5283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Menon D Ravindran, Das S, Krepler C,
Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad E
Bonyadi, et al: A stress-induced early innate response causes
multidrug tolerance in melanoma. Oncogene. 34:4448–4459. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sharma BK, Manglik V, O'Connell M,
Weeraratna A, McCarron EC, Broussard JN, Divito KA,
Simbulan-Rosenthal CM, Rosenthal DS and Zapas JL: Clonal dominance
of CD133+ subset population as risk factor in tumor progression and
disease recurrence of human cutaneous melanoma. Int J Oncol.
41:1570–1576. 2012.PubMed/NCBI
|
|
43
|
Chartrain M, Riond J, Stennevin A,
Vandenberghe I, Gomes B, Lamant L, Meyer N, Gairin JE, Guilbaud N
and Annereau JP: Melanoma chemotherapy leads to the selection of
ABCB5-expressing cells. PLoS One. 7:e367622012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
46
|
Ren F, Sheng WQ and Du X: CD133: A cancer
stem cells marker, is used in colorectal cancers. World J
Gastroenterol. 19:2603–2611. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Quintana E, Shackleton M, Sabel MS, Fullen
DR, Johnson TM and Morrison SJ: Efficient tumour formation by
single human melanoma cells. Nature. 456:593–598. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Velarde MC, Flynn JM, Day NU, Melov S and
Campisi J: Mitochondrial oxidative stress caused by Sod2 deficiency
promotes cellular senescence and aging phenotypes in the skin.
Aging (Albany NY). 4:3–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Achuthan S, Santhoshkumar TR, Prabhakar J,
Nair SA and Pillai MR: Drug-induced senescence generates
chemoresistant stemlike cells with low reactive oxygen species. J
Biol Chem. 286:37813–37829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Leikam C, Hufnagel AL, Otto C, Murphy DJ,
Mühling B, Kneitz S, Nanda I, Schmid M, Wagner TU, Haferkamp S, et
al: In vitro evidence for senescent multinucleated melanocytes as a
source for tumor-initiating cells. Cell Death Dis. 6:e17112015.
View Article : Google Scholar : PubMed/NCBI
|
